Imipenem Cilastatine Panpharma

Imipenem/cilastatin, the active ingredient in Imipenem Cilastatine Panpharma, is a carbapenem antibiotic presented as an intravenous formulation for intravenous use. It treats serious bacterial infections such as complicated intra‑abdominal, urinary tract, skin and soft‑tissue infections, as well as community‑acquired and hospital‑acquired pneumonia in hospitalized adult patients.

GNH USA supplies Imipenem Cilastatine Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/cilastatin is used to treat severe bacterial infections affecting various organ systems. - Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens to resolve infection. - Complicated urinary tract infections: eliminates resistant Gram‑negative organisms causing pyelonephritis. - Skin and soft‑tissue infections: provides broad‑spectrum coverage for serious cellulitis and abscesses. - Community‑acquired and hospital‑acquired pneumonia: targets common and resistant respiratory pathogens. - Severe sepsis and septic shock: delivers rapid bactericidal activity in critical care settings.

Adverse reactions to imipenem/cilastatin may range from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: may be watery or loose. - Rash: mild skin erythema or pruritus. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Seizures: especially in patients with CNS disorders or high doses. - Anaphylaxis: severe allergic reaction with respiratory compromise. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Neutropenia: marked reduction in white blood cells.

When prescribing imipenem/cilastatin, clinicians should consider the following precautions. - Renal function: adjust dosing in patients with impaired kidney function. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: monitor patients with a history of seizures or CNS disorders. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Drug interactions: review concomitant medications for possible interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/cilastatin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Valproic acid: reduces serum levels, increasing seizure risk. - CNS stimulants: may potentiate seizure activity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity. - Loop diuretics: may increase renal toxicity. - Probenecid: may reduce renal clearance of imipenem. - Warfarin: may alter INR and affect anticoagulation control.